15:49 EST Correction: Seres reports Q3 EPS from continuing operations (33c)
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB:
- Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success
- Seres Therapeutics reports Q3 EPS 58c, consensus (24c)
- Seres Therapeutics expects cash to fund operations into Q4 of 2025
- Seres Therapeutics Inc. (MCRB) Q3 Earnings Cheat Sheet
- Seres Therapeutics downgraded to Underweight from Neutral at JPMorgan